Gottart

Gottart is a prescription oral medication that contains the active ingredient febuxostat, a selective non‑purine xanthine oxidase inhibitor. It is marketed in the European Union for the management of hyperuricemia and gout, helping to lower elevated uric acid levels in the blood.

Gottart is indicated for patients who need long‑term reduction of serum uric acid. It is commonly prescribed in the following situations:

- Management of chronic gout in adults who have an inadequate response to allopurinol. - Treatment of hyperuricemia associated with chemotherapy or tumor lysis syndrome. - Prevention of gout flares in patients with recurrent attacks. - Adjunct therapy for patients with renal impairment where dose adjustment of other urate‑lowering agents is required. - Use in patients with contraindications to other xanthine oxidase inhibitors.

Side effects of Gottart vary in frequency and severity. Common reactions are usually mild and transient, while serious events are less frequent but require medical attention.

Common: - Headache - Nausea or vomiting - Diarrhea - Elevated liver enzymes - Mild rash or pruritus - Dizziness

Serious: - Severe hypersensitivity reactions, including Stevens‑Johnson syndrome - Hepatotoxicity presenting as jaundice or significant transaminase elevation

Before starting Gottart, certain health considerations should be reviewed to ensure safe use. Important precautions include:

- Assess liver function; avoid use in patients with active hepatic disease. - Evaluate renal function; dose adjustment may be needed in severe impairment. - Screen for cardiovascular disease, as febuxostat has been linked to increased risk of major adverse events. - Avoid use during pregnancy and lactation unless clearly indicated. - Monitor serum uric acid levels regularly to gauge therapeutic response. - Discontinue if a severe hypersensitivity reaction occurs.

Gottart can interact with several medications, affecting its efficacy or safety profile. Interactions are grouped by the level of risk.

Avoid: - Azathioprine or mercaptopurine, which may increase toxicity due to reduced metabolism. - High‑dose aspirin, which can diminish uric acid‑lowering effect. - Certain antiretroviral agents (e.g., ritonavir) that inhibit CYP enzymes involved in febuxostat metabolism.

Use with caution: - Warfarin, as febuxostat may enhance anticoagulant effect and require INR monitoring. - Simvastatin or other statins, due to potential increase in statin plasma concentrations.